JD Supra2d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Hosted on MSN7d
The FDA is about to make weight-loss drugs a lot harder to get
DeBenedetto's excitement has been stunted, however, by recent developments that will make compounded tirzepatide no longer ...
ENDPOINTS NEWS1d
Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
pharmaphorum15h
Ozempic is first GLP-1 drug FDA-approved for kidney disease
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
pulmonologyadvisor5d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Healio11h
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
AOL7d
The FDA is about to make weight-loss drugs a lot harder to get
DeBenedetto's excitement has been stunted, however, by recent developments that will make compounded tirzepatide no longer widely available. The FDA has removed the drug from its shortage list and ...